The 2007 ASCO/CAP HER2 Guidelines25 in breast cancer demands HER2-immunoreactivity/amplification in at least 30% of breast cancer tumour areas in order to render a HER2-positivity as a conclusion. The gene discussed is ERBB2; the disease is neoplasm.